In a multicenter study, treatment with cyclosporine did not prevent early multiple organ failure when administered after out-of-hospital cardiac arrest.
Results from the Cyclosporine A in Out-0f-Hospital Cardiac Arrest Resuscitation (CYRUS) trial corresponded with those of the recently published CIRCUS trial, in which administration of cyclosporine showed no benefit when given immediately after reperfusion injury in patients with acute myocardial infarction.
In the CYRUS study, treatment with 2.5 mg/kg IV bolus injection of cyclosporine given at the onset of advanced cardiovascular life support following cardiac arrest was not associated with a reduction in organ failure, as measured by Sequential Organ Failure Assessment (SOFA) score (median 10, interquartile range [IQR] 7-13 versus median 11, IQR 7-15 among controls), Laurent Argaud, MD, PhD, of Hospices Civils de Lyon, France, and colleagues reported online in JAMA Cardiology.
Survival among patients who suffer nonshockable out-of-hospital cardiac arrest is very low, with less than 3% of patients in one study surviving to hospital discharge.
The researchers noted that therapeutic resumption of blood circulation, which is a primary therapeutic objective of cardiac resuscitation, is associated with risk for reperfusion injury and long-term injury.